One-Time cell infusion could free kidney patients from lifelong drug burden

NCT ID NCT06552169

Recruiting now Disease control Sponsor: Singulera Therapeutics Inc. Source: ClinicalTrials.gov ↗

Summary

This trial is testing whether a one-time infusion of specially grown immune cells can help prevent a patient's body from rejecting a new kidney. The goal is to see if this cell therapy allows patients to safely take fewer anti-rejection drugs long-term. Researchers will compare patients receiving the cell therapy plus standard drugs against those receiving only standard drugs, following all participants for five years after their transplant.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chang Gung Medical Foundation Hospital
RECRUITING

Taoyuan District, 333, Taiwan

Contact
Mayo Clinic in Arizona
NOT_YET_RECRUITING

Phoenix, Arizona, 85054, United States

Contact
Mayo Clinic in Minnesota
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States

Contact
National Cheng Kung University Hospital
NOT_YET_RECRUITING

Tainan, 704, Taiwan

Contact
National Taiwan University Hospital
RECRUITING

Taipei, 100229, Taiwan

Contact
Northwestern Memorial Hospital
RECRUITING

Chicago, Illinois, 60611, United States

Contact
Taichung Veterans General Hospital
RECRUITING

Taichung, 407219, Taiwan

Contact

Conditions

Explore the condition pages connected to this study.

KIDNEY TRANSPLANTATION